ndv-01
ndv-01: developed by 1 company · 3 clinical trials tracked.
ndv-01 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could ndv-01 → RLMD affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Uro… | Phase 3 |
Clinical Trials (3)
A Phase 3 Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
Primary endpoint: To evaluate the efficacy of NDV-01 (determined by complete response [CR] anytime) administered by intravesical instillation in patients with BCG-unresponsive NMIBC who have recurred after first-line intravesical therapy (approved or in development).
A Phase 3 Study Evaluating the Efficacy and Safety of NDV-01 in Participants With Non-muscle Invasive Bladder Cancer (RESCUE)
Primary endpoint: Disease Free Survival in participants with Intermediate Risk NMIBC
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of NDV-01 Versus Observation in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (BOOST)
Primary endpoint: To compare DFS between study arms
Frequently asked questions
Who is developing ndv-01?
ndv-01 is being developed by RELMADA THERAPEUTICS, INC..
How many clinical trials involve ndv-01?
BioSniper tracks 3 clinical trials involving ndv-01.